Project Grant R01AI190038
Award Date
2/24/25
Completion Date
1/31/30
Dollars Obligated
$775K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop novel pro-apoptotic (cell death-inducing) small molecule therapies as a host-directed treatment for pulmonary tuberculosis (TB). The $817,941 award to The Johns Hopkins University will leverage cutting-edge imaging technologies and high-dimensional immunophenotyping to gain mechanistic insights on how...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA program 93.855 Allergy and Infectious Diseases Research, will fund a $127,980 research initiative at The Johns Hopkins University over a 5-year period from September 1, 2024 to August 31, 2029. The project aims to identify more effective and efficient approaches for community-based tuberculosis (TB) screening and prevention by leveraging emerging data sources such as cell...
This $749,414 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The primary awardee, The Ohio State University, is conducting research to investigate the role of the macrophage efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and its impact on tuberculosis (TB) treatment duration. The research aims to: 1) define the role of MDR1 in M.TB survival in macrophages;...
This federal Project Grant award of $1,615,826.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the molecular basis of antibiotic resilience in Mycobacterium tuberculosis. The primary awardee, Harvard College President & Fellows Of, will lead a multidisciplinary effort to study a novel transcriptional regulatory network that controls antibiotic resilience...
This $1,297,775 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to investigate the role of sirtuins, a type of protein, in regulating the interactions between tuberculosis (TB) and HIV infections in macrophages. The primary goal is to develop an innovative immunochemotherapy approach to eradicate TB-HIV coinfections. The research aims to analyze how early TB and HIV infections impact...
This $899,894 Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate early immune cell interactions and signaling pathways that contribute to tuberculosis (TB) disease outcomes during HIV/TB co-infection. The primary awardee, The Washington University in St. Louis, will lead studies to define the roles of type I interferon (IFN) signaling and...
This federal Project Grant award of $787,171, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of new antituberculosis (TB) compounds based on 1,2,4-triazole and pyrrolidine scaffolds. The primary awardee, Washington University in St. Louis, aims to demonstrate preclinical proof-of-concept for these compounds, optimize lead candidates for pharmacological properties, and...
This federal Project Grant award of $1,185,782.00, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to transform global tuberculosis (TB) research by accelerating the study of human TB lung tissue. The primary goals are to provide two key services to the TB research community: (1) performing pathological, cellular, structural, and/or genetic analysis of resected human TB or postmortem...
This $1,350,312 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 - Allergy and Infectious Diseases Research program supports the development of a rapid, phenotypic drug susceptibility testing (DST) system for tuberculosis (TB). The primary goal is to design and optimize a novel, trehalose-based DST (TRE-DST) that can accurately diagnose TB drug resistance, including for first- and second-line TB drugs. This includes developing and...
This $246,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of lung repair and regeneration pathways in tuberculosis (TB). The primary objectives are to determine the functional role of the bone morphogenetic protein (BMP) signaling pathway in controlling TB infection and reactivation, as well as characterize the cellular mechanisms...